30-day average of 12 articles · scale −100 to +100
Across 12 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Gilead Sciences news is Somewhat Bullish (+50)
on a scale from −100 to +100.
That is up 9 points from the previous 30 days (+41).
📈 Gilead Q3 EPS beat estimates by 15.6%, extending six quarters of outperformance.
💰 Revenue rose 6.8% YoY to $8.3B driven by strong HIV franchise performance.
Bullish +65
Gilead Sciences (GILD) Q3 2026 Earnings
AI-generated analysis
Key insights
📈 Gilead reported Q3 2026 non-GAAP EPS of $2.55, beating the $2.21 consensus estimate by 15.6% and extending a six-quarter run of exceeding analyst expectations.
💰 Revenue reached $8.3 billion, topping the $7.8 billion estimate by 6.32% and rising 6.8% year over year driven by strong HIV franchise performance.
🔬 HIV sales surged 18% to drive overall growth, with Biktarvy up 10% and prevention revenues nearly doubling due to the rapid commercial ramp of Yeztugo.
📊 Product sales excluding Veklury increased 16% to $8.20 billion, fueled by higher average realized prices and favorable inventory dynamics across key assets.
🚀 Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, a cumulative increase of $1.60 billion since the start of the year.
⚖️ Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, improving profitability on core products.
📉 GAAP diluted EPS declined to $1.94 from the prior year due to net losses from equity securities and higher tax rates, masking underlying operational strength.
💸 Significant acquired IPR&D charges of $12.4 billion are included in guidance, resulting in a projected GAAP diluted loss of $(4.40)–$(4.05) per share for the full year.
📉 Veklury revenues dropped 69% to approximately $300 million as expected due to lower COVID-19 hospitalizations, though guidance remains unchanged at this level.
⚠️ The Biktarvy Medicare Maximum Fair Price is scheduled to affect revenue starting January 1, 2028, potentially impacting future HIV franchise growth.
📈 Bullish signals
📈Gilead delivered a standout Q3 with non-GAAP EPS of $2.55, beating estimates by 15.6% and extending a six-quarter streak of exceeding analyst expectations.
💰Revenue of $8.3 billion surpassed the $7.8 billion consensus, rising 6.8% year over year driven by an 18% surge in HIV sales.
🔬The twice-yearly lenacapavir PrEP product Yeztugo rapidly ramped to generate $305 million, a near-doubling of prevention revenues compared to the prior year.
📊Product sales excluding Veklury grew 16% to $8.20 billion, fueled by higher average realized prices and strong demand for Biktarvy and Descovy.
🚀Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, reflecting confidence in its core business momentum.
⚖️Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, enhancing profitability on existing assets.
📉 Risk factors
📉GAAP diluted EPS fell to $1.94 from the prior year due to net losses from equity securities and higher operating expenses.
💸Significant acquired IPR&D charges of $12.4 billion weigh heavily on per-share metrics, resulting in a projected full-year GAAP loss of $(4.40)–$(4.05).
📉Cell therapy revenues declined 18% year over year due to competitive headwinds in the sector.
📉Veklury revenues dropped 69% to approximately $300 million as lower COVID-19 hospitalizations reduced demand for the antiviral treatment.
Article
Gilead Sciences reported third-quarter fiscal 2026 earnings on October 29, 2026, significantly beating analyst expectations with non-GAAP EPS of $2.55 versus a consensus of $2.21 and revenue of $8.3 billion against an estimate of $7.8 billion. This performance extended the company's streak of exceeding EPS estimates to six consecutive quarters, driven primarily by robust growth in its HIV franchise where product sales excluding Veklury surged 16% year-over-year.
The standout quarter was fueled by an 18% increase in HIV sales led by the blockbuster drug Biktarvy and a near-doubling of prevention revenues. The twice-yearly lenacapavir PrEP product, Yeztugo, rapidly ramped up to generate $305 million compared to just $39 million a year earlier. Other segments showed mixed results, with liver disease sales rising 13% due to Livdelzi demand and pricing, while cell therapy revenues declined 18% amid competitive headwinds.
Despite the strong operational performance, GAAP diluted EPS fell to $1.94 from the prior year due to net losses on equity securities and higher operating expenses. Gilead raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion, reflecting confidence in its core business despite significant acquired IPR&D charges totaling $12.4 billion that weigh heavily on per-share metrics.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Gilead Sciences reported third-quarter fiscal 2026 earnings on October 29, 2026, significantly beating analyst expectations with non-GAAP EPS of $2.55 versus a consensus of $2.21 and revenue of $8.3 billion against an estimate of $7.8 billion. This performance extended the company's streak of exceeding EPS estimates to six consecutive quarters, driven primarily by robust growth in its HIV franchise where product sales excluding Veklury surged 16% year-over-year.
The standout quarter was fueled by an 18% increase in HIV sales led by the blockbuster drug Biktarvy and a near-doubling of prevention revenues. The twice-yearly lenacapavir PrEP product, Yeztugo, rapidly ramped up to generate $305 million compared to just $39 million a year earlier. Other segments showed mixed results, with liver disease sales rising 13% due to Livdelzi demand and pricing, while cell therapy revenues declined 18% amid competitive headwinds.
Despite the strong operational performance, GAAP diluted EPS fell to $1.94 from the prior year due to net losses on equity securities and higher operating expenses. Gilead raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion, reflecting confidence in its core business despite significant acquired IPR&D charges totaling $12.4 billion that weigh heavily on per-share metrics.
📈 Gilead Q3 EPS beat estimates by 15.6%, extending six quarters of outperformance.
💰 Revenue rose 6.8% YoY to $8.3B driven by strong HIV franchise performance.
🔬 HIV sales surged 18% as Yeztugo ramp and Biktarvy grew 10%.
🚀 Full-year 2026 sales guidance raised to $31.0–$31.3 billion.
⚠️ Biktarvy Medicare pricing changes may impact HIV growth starting Jan 2028.
📈 Gilead reported Q3 2026 non-GAAP EPS of $2.55, beating the $2.21 consensus estimate by 15.6% and extending a six-quarter run of exceeding analyst expectations.
💰 Revenue reached $8.3 billion, topping the $7.8 billion estimate by 6.32% and rising 6.8% year over year driven by strong HIV franchise performance.
🔬 HIV sales surged 18% to drive overall growth, with Biktarvy up 10% and prevention revenues nearly doubling due to the rapid commercial ramp of Yeztugo.
📊 Product sales excluding Veklury increased 16% to $8.20 billion, fueled by higher average realized prices and favorable inventory dynamics across key assets.
🚀 Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, a cumulative increase of $1.60 billion since the start of the year.
⚖️ Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, improving profitability on core products.
📉 GAAP diluted EPS declined to $1.94 from the prior year due to net losses from equity securities and higher tax rates, masking underlying operational strength.
💸 Significant acquired IPR&D charges of $12.4 billion are included in guidance, resulting in a projected GAAP diluted loss of $(4.40)–$(4.05) per share for the full year.
📉 Veklury revenues dropped 69% to approximately $300 million as expected due to lower COVID-19 hospitalizations, though guidance remains unchanged at this level.
⚠️ The Biktarvy Medicare Maximum Fair Price is scheduled to affect revenue starting January 1, 2028, potentially impacting future HIV franchise growth.
Bullish Signals
Non-GAAP EPS hit $2.55, beating estimates by 15.6%.
Revenue reached $8.3B, up 6.8% YoY driven by HIV sales.
Product sales excluding Veklury grew 16% to $8.20B.
Raised full-year 2026 guidance to $31.0–$31.3 billion.
Gross margin expanded to 81.0% non-GAAP.
Risk Factors
GAAP EPS fell to $1.94 due to higher expenses and equity losses.
Acquired IPR&D charges of $12.4B project a full-year loss of $(4.05).
Cell therapy revenues declined 18% due to sector competitive headwinds.
Veklury revenues dropped 69% as lower COVID hospitalizations reduced demand.
Bullish Signals
Gilead delivered a standout Q3 with non-GAAP EPS of $2.55, beating estimates by 15.6% and extending a six-quarter streak of exceeding analyst expectations.
Revenue of $8.3 billion surpassed the $7.8 billion consensus, rising 6.8% year over year driven by an 18% surge in HIV sales.
The twice-yearly lenacapavir PrEP product Yeztugo rapidly ramped to generate $305 million, a near-doubling of prevention revenues compared to the prior year.
Product sales excluding Veklury grew 16% to $8.20 billion, fueled by higher average realized prices and strong demand for Biktarvy and Descovy.
Gilead raised full-year 2026 product sales guidance to $31.0–$31.3 billion, reflecting confidence in its core business momentum.
Product gross margin expanded to 81.0% non-GAAP following the expiration of a royalty-related obligation, enhancing profitability on existing assets.
Risk Factors
GAAP diluted EPS fell to $1.94 from the prior year due to net losses from equity securities and higher operating expenses.
Significant acquired IPR&D charges of $12.4 billion weigh heavily on per-share metrics, resulting in a projected full-year GAAP loss of $(4.40)–$(4.05).
Cell therapy revenues declined 18% year over year due to competitive headwinds in the sector.
Veklury revenues dropped 69% to approximately $300 million as lower COVID-19 hospitalizations reduced demand for the antiviral treatment.
Gilead Sciences received fresh positive data from its Phase 2 PURPOSE 5 study, presented ahead of the HIV Glasgow 2026 congress. The trial compared twice-yearly injectable lenacapavir against daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis in patients in the UK and France who were not previously taking PrEP.
The study results demonstrated a significant advantage in persistence, with 85.6% of participants on lenacapavir remaining adherent at Week 52 compared to only 46.3% for the daily F/TDF group. Furthermore, no HIV acquisitions occurred in the lenacapavir cohort, whereas one case was observed in the control group, consistent with low drug levels.
This data strengthens Gilead's long-acting HIV prevention strategy by addressing adherence constraints that often limit the effectiveness of daily oral regimens. While the findings support the commercial potential of a six-month dosing schedule, investors are now evaluating whether this persistence advantage translates into durable demand and how these new regimens fit within Gilead's broader HIV portfolio.
Gilead Sciences stock was trading at 151.69 euros on November 10, 2026. The company is also highlighting other evidence involving Biktarvy and investigational once-weekly or twice-yearly injectable treatments at the congress, though this specific study adds clinical support without establishing future sales figures on its own.
📈 85.6% persistence rate for lenacapavir outperforms daily oral F/TDF at Week 52.
🛡️ Zero HIV acquisitions observed in Phase 2 trial versus one in comparator group.
💉 Six-month dosing schedule enhances continuity over daily oral regimens for PrEP.
🏥 Additional evidence for Biktarvy and injectables presented at HIV Glasgow 2026 congress.
💰 Stock traded at 151.69 euros on November 10, 2026 following positive data release.
📈 Gilead Sciences reported that 85.6% of participants in the PURPOSE 5 study remained persistent on twice-yearly lenacapavir at Week 52, significantly outperforming the 46.3% persistence rate of daily oral F/TDF.
🛡️ The Phase 2 trial showed zero HIV acquisitions among patients receiving lenacapavir, compared to one acquisition in the F/TDF group where drug levels were low.
💉 Gilead's data supports its long-acting HIV prevention strategy by demonstrating that a six-month dosing schedule improves continuity over daily oral regimens.
📊 The study enrolled patients in the UK and France who needed pre-exposure prophylaxis but were not taking PrEP at enrollment.
🏥 Gilead is presenting additional evidence for Biktarvy and investigational once-weekly or twice-yearly injectable treatments at the HIV Glasgow 2026 congress.
💰 Gilead Sciences stock traded at 151.69 euros on November 10, 2026, following the release of the positive clinical data.
Bullish Signals
85.6% adherence in Phase 2 PURPOSE 5 study vs 46.3% for oral F/TDF.
Zero HIV acquisitions in lenacapavir group validates long-acting injectable prevention strategy.
Gilead Sciences demonstrated superior persistence in its Phase 2 PURPOSE 5 study, with 85.6% of patients remaining adherent to twice-yearly lenacapavir versus 46.3% for daily oral F/TDF at Week 52.
The company reported zero HIV acquisitions in the lenacapavir group compared to one in the control group, validating the efficacy of its long-acting injectable prevention strategy.
Fresh clinical evidence strengthens Gilead's long-acting HIV portfolio by addressing adherence constraints that limit real-world effectiveness of daily oral regimens.
Gilead Sciences is set to present data from over 50 studies at the HIV Glasgow conference running from November 8 to 11, 2026. The presentations will cover its pipeline in prevention, treatment, and cure research, with a specific focus on long-acting regimens that could shape the company's long-term growth strategy.
The core of the presentation includes updates on twice-yearly lenacapavir from the Phase 2 PURPOSE 5 study, real-world outcomes for Biktarvy, and Phase 3 results for the ARTISTRY combination. Additionally, Gilead will present data on an investigational once-weekly oral regimen combining islatravir and lenacapavir (ISLEND) and early-stage data on GS-3242.
While the company recently received FDA approval for Bixlenvo in August 2026, the upcoming clinical readouts are viewed as fundamental catalysts rather than immediate revenue drivers. The presentations aim to demonstrate Gilead's ability to extend its leadership through less frequent dosing options while balancing established commercial products against programs facing ongoing clinical and regulatory risks.
Gilead Sciences stock traded at 150.25 euros on November 9, slightly above the previous Friday close. Investors are watching these data points to assess whether Gilead can successfully transition its HIV portfolio toward longer-acting therapies that improve patient adherence and real-world effectiveness.
📅 Gilead presents 50+ HIV study results at Glasgow conference Nov 8-11, 2026.
💉 Focus on twice-yearly lenacapavir and once-weekly islatravir/lenacapavir oral combination.
✅ FDA approved Bixlenvo in August 2026 for switching virologically suppressed adults.
⚠️ Investigational agents GS-3242 and amtabafusp alfa lack approval or established safety.
📈 Stock at 150.25 euros reflects investor interest in upcoming clinical data.
📅 Gilead Sciences will present results from more than 50 studies at the HIV Glasgow conference from November 8 to 11, 2026.
💉 The company is focusing on long-acting regimens, including twice-yearly lenacapavir and an investigational once-weekly oral combination of islatravir and lenacapavir.
📊 Key presentations include Phase 2 data from the PURPOSE 5 study evaluating persistence with twice-yearly lenacapavir versus daily Truvada.
💊 Gilead will share real-world outcomes for Biktarvy and Phase 3 results for the ARTISTRY BIC/LEN combination therapy.
🔬 The company plans to present Phase 1b data on GS-3242, an investigational integrase inhibitor studied with lenacapavir as a potential twice-yearly injectable.
🏥 ISLEND trials will cover efficacy and safety of the once-weekly oral regimen in diverse populations, including patients switching from existing treatments.
✅ The U.S. FDA approved Bixlenvo in August 2026 for adults with HIV who are virologically suppressed and switching regimens.
🧬 Gilead provided an update on amtabafusp alfa, a bispecific T-cell engager being studied in a Phase 1b trial for HIV cure research.
⚠️ The company cautions that investigational agents like GS-3242 and amtabafusp alfa have not yet received approval or established safety and efficacy.
📈 Gilead Sciences stock traded at 150.25 euros on November 9, 2026, reflecting investor interest in the upcoming clinical data.
🎯 Upcoming HIV data is expected to help investors assess Gilead's ability to extend leadership through longer-acting and less frequent dosing options.
⚖️ The company is balancing established commercial products with several programs that still face significant clinical and regulatory risk.
Bullish Signals
Gilead presents 50+ HIV study results at Glasgow conference.
Advancing long-acting lenacapavir and islatravir oral regimens.
FDA approved Bixlenvo in August 2026 for HIV.
Plans to present Biktarvy real-world outcomes data.
Programs GS-3242 and amtabafusp alfa await FDA approval.
Established products balanced against ongoing clinical/regulatory risks.
PURPOSE 5 study results not yet released.
Bullish Signals
Gilead Sciences will present results from more than 50 studies at the HIV Glasgow conference, providing significant pipeline visibility to investors.
The company is advancing long-acting regimens including twice-yearly lenacapavir and an investigational once-weekly oral combination of islatravir and lenacapavir.
Gilead recently received FDA approval for Bixlenvo in August 2026, expanding its portfolio of approved HIV treatments.
The company plans to present real-world outcomes for Biktarvy, which can influence commercial adoption and real-world effectiveness.
Phase 3 ARTISTRY results for the once-daily BIC/LEN combination will be discussed, offering data on established therapeutic combinations.
Risk Factors
The upcoming clinical presentations offer pipeline visibility rather than a confirmed near-term revenue contribution for investigational agents.
Several programs presented, including GS-3242 and amtabafusp alfa, have not yet received FDA approval or established safety and efficacy.
Gilead is balancing its established commercial products with several programs that still face ongoing clinical and regulatory risk.
The final results for the PURPOSE 5 study evaluating twice-yearly lenacapavir had not been released at the time of the announcement.
Gilead Sciences (GILD) reported a trailing twelve-month loss of $3.13 per share, driven primarily by approximately $12 billion in acquired in-process R&D charges recorded in the June quarter. Despite this accounting-driven negative earnings figure, the company maintains a robust financial position with free cash flow covering its dividend payments roughly 4.6 times over in the third quarter.
The core business demonstrated resilience with third-quarter revenue reaching $8.30 billion and non-GAAP EPS of $2.55 beating analyst consensus. HIV sales grew by 18%, while Yeztugo, a twice-yearly HIV prevention shot, saw quarterly sales climb to $305 million. Management expects total HIV revenue, product sales, and EPS to grow in 2028 compared with 2027.
Gilead raised its quarterly dividend to $0.82 and declared another $0.82 payout for the fourth quarter, payable December 30, 2026. Adjusted non-GAAP full-year EPS is projected between $8.75 and $9.10, resulting in a payout ratio of roughly 36% to 37%. The stock trades at $168.38, up 39.65% year to date, reflecting investor confidence in the dividend's safety despite the headline loss.
📉 Q3 trailing EPS was -$3.13 due to $12B acquired R&D charges.
💰 Q3 free cash flow of $4.798B covers the dividend 4.6 times.
📈 Q3 revenue hit $8.30B with non-GAAP EPS of $2.55 beating estimates.
💊 HIV sales rose 18% while Yeztugo sales climbed to $305M.
⚠️ Biktarvy faces a $1.5B net revenue hit starting Jan 1, 2028.
📉 Gilead reported a trailing EPS of -$3.13 due to approximately $12 billion in acquired in-process R&D charges from deals with Arcellx, Tubulis, Ouro Medicines, and PepStar.
💰 Free cash flow of $4.798 billion in the third quarter covers the dividend about 4.6 times over, indicating a safe payout despite negative accounting earnings.
📈 Third-quarter revenue reached $8.30 billion with non-GAAP EPS of $2.55 beating the $2.21 consensus estimate.
💊 HIV sales rose 18% in the quarter, fueling core growth and contributing to overall financial stability.
🚀 Yeztugo quarterly sales climbed from $166 million to $305 million, with management expecting about $1 billion in full-year sales.
💵 Gilead raised its quarterly dividend to $0.82 and declared an additional $0.82 payout for Q4 2026, payable December 30.
📊 Adjusted non-GAAP full-year EPS is forecast between $8.75 and $9.10, implying a payout ratio of roughly 36% to 37%.
📈 The stock price increased 39.65% year to date, trading at $168.38 as investors focus on cash flow rather than headline EPS.
⚠️ Starting Jan 1, 2028, Biktarvy faces a Medicare Maximum Fair Price with a preliminary net revenue hit of about $1.5 billion.
🔮 Management projects total HIV revenue, product sales, and EPS to grow in 2028 compared with 2027.
Bullish Signals
Free cash flow of $4.798B covers dividend 4.6x.
Q3 revenue hit $8.30B with EPS of $2.55.
HIV sales rose 18% showing strong core growth.
Yeztugo sales climbed to $305M, nearing $1B.
Dividend raised to $0.82 with additional $0.82.
Risk Factors
Trailing EPS is -$3.13 due to $12B in R&D charges.
Biktarvy faces $1.5B net revenue hit starting 2028.
Cash fell 12.18% to $6.437B after acquisitions.
Bullish Signals
Free cash flow of $4.798 billion covers the dividend about 4.6 times over, providing a strong safety margin for the payout.
Third-quarter revenue reached $8.30 billion with non-GAAP EPS of $2.55 beating the $2.21 consensus estimate.
HIV sales rose 18% in the quarter, demonstrating strong core business growth and market demand.
Yeztugo quarterly sales climbed to $305 million, up from $166 million a year prior, with full-year expectations near $1 billion.
The company raised its quarterly dividend to $0.82 and declared an additional $0.82 payout for Q4 2026.
Adjusted non-GAAP full-year EPS is projected between $8.75 and $9.10, resulting in a conservative payout ratio of roughly 36% to 37%.
The stock price surged 39.65% year to date, trading at $168.38 as investors recognize the value of its cash generation.
Risk Factors
Trailing EPS is -$3.13 due to approximately $12 billion in acquired in-process R&D charges recorded in the June quarter.
Starting Jan 1, 2028, Biktarvy faces a Medicare Maximum Fair Price with a preliminary net revenue hit of about $1.5 billion.
Cash and equivalents fell 12.18% to $6.437 billion following recent acquisitions.
Gilead Sciences reported positive Phase 3 IDEAL trial results for its drug Livdelzi in patients with primary biliary cholangitis (PBC) who had lower alkaline phosphatase levels. The study demonstrated that at Week 52, 75.4% of participants receiving Livdelzi achieved the composite endpoint of normalized alkaline phosphatase levels and a significant reduction from baseline, compared to only 16.1% on placebo.
The treatment showed an early response, with over half of the patients reaching the primary endpoint after just one month versus 6.5% in the placebo group. The safety profile remained consistent with earlier studies, showing serious adverse events in 3.1% of Livdelzi participants compared to 12.9% on placebo, with none attributed to the trial drug.
Gilead plans to engage global regulatory authorities regarding these findings, which will be presented at The Liver Meeting in Denver and published in the Journal of Hepatology. While Livdelzi already holds accelerated approval in the US for specific PBC populations, broader use depends on confirmatory evidence demonstrating survival improvement or prevention of liver decompensation.
Following the news, Gilead Sciences stock traded 3.93% below the previous day's Xetra close at 147.08 euros. The company faces a regulatory test to expand the drug's label beyond its current indications, with future developments hinging on discussions with health authorities and the presentation of IDEAL data.
📈 Gilead's Livdelzi showed 75.4% alkaline phosphatase normalization vs 16.1% placebo in Phase 3 IDEAL.
⚡ Early treatment effect reached 52.3% composite endpoint after one month versus 6.5% placebo.
🛡️ Serious adverse events were 3.1% for Livdelzi participants versus 12.9% on placebo.
🗣️ Gilead seeks broader global authorization for Livdelzi based on IDEAL study results.
💊 Livdelzi has US accelerated approval pending confirmatory survival or liver decompensation evidence.
📈 Gilead Sciences reported strong Phase 3 IDEAL results showing 75.4% of patients achieved alkaline phosphatase normalization at Week 52 versus 16.1% on placebo.
🔬 The study enrolled 96 adults with primary biliary cholangitis who had inadequate control or could not tolerate ursodeoxycholic acid treatment.
⚡ Treatment effect appeared early with 52.3% of participants reaching the composite endpoint after one month compared to 6.5% in the placebo group.
🛡️ Safety profile remained consistent with earlier studies, with serious adverse events occurring in only 3.1% of Livdelzi participants versus 12.9% on placebo.
🗣️ Gilead plans discussions with global regulatory authorities to seek broader authorization for Livdelzi based on the IDEAL study results.
📅 The findings will be presented at The Liver Meeting in Denver from November 5 to 9 and accepted for publication in the Journal of Hepatology.
💊 Livdelzi currently has accelerated approval in the US but requires confirmatory evidence regarding survival improvement or prevention of liver decompensation.
📉 Gilead Sciences stock traded at 147.08 euros on November 6, 2026, representing a 3.93% decline from the previous day's Xetra close.
Bullish Signals
Livdelzi showed 75.4% response rate vs 16.1% placebo in PBC.
Early effect: 52.3% reached endpoint after one month vs 6.5% placebo.
Safety favored with 3.1% serious adverse events vs 12.9% on placebo.
Risk Factors
Livdelzi approval depends on unproven survival benefits.
Gilead Sciences reported positive Phase 3 IDEAL trial results for Livdelzi in a new patient population with primary biliary cholangitis, achieving a 75.4% response rate at Week 52 compared to 16.1% on placebo.
The drug demonstrated an early treatment effect with 52.3% of participants reaching the composite endpoint after just one month versus 6.5% in the placebo group.
Livdelzi maintained a favorable safety profile with serious adverse events occurring in only 3.1% of patients on the drug compared to 12.9% on placebo, and no serious adverse events were considered related to the trial drug.
Risk Factors
Gilead faces regulatory hurdles as broader use of Livdelzi depends on confirmatory evidence demonstrating survival improvement or prevention of liver decompensation, which has not yet been demonstrated.
The company's next step involves regulatory discussions rather than an immediate label expansion, leaving the timing and scope of any broader authorization open.
Gilead Sciences announced positive Phase 3 IDEAL study results for its drug Livdelzi in patients with primary biliary cholangitis (PBC). The trial evaluated the treatment in adults with moderately elevated alkaline phosphatase levels who had either failed ursodeoxycholic acid therapy or could not tolerate it. The data was published by Business Wire ahead of a presentation at The Liver Meeting in Denver.
At Week 52 of the study, 75.4% of participants receiving Livdelzi achieved the composite endpoint for alkaline phosphatase normalization, compared to only 16.1% of those on placebo. This response was observed after one month and remained sustained through the end of the trial period. The results significantly expand the clinical evidence base for Livdelzi in this specific patient population.
Following the positive data, Gilead plans to engage with global regulatory authorities to discuss potential future pathways for the drug. While this engagement does not represent an immediate approval or filing announcement, it marks a significant milestone for the company's liver disease pipeline. The stock price reflected the news, trading 1.75% higher on Thursday.
📈 Gilead's Livdelzi showed 75.4% efficacy vs 16.1% placebo in Phase 3 IDEAL study.
🔬 Trial enrolled adults with elevated ALP levels despite prior ursodeoxycholic acid treatment.
🗣️ Gilead plans to engage global regulators based on these positive clinical milestone results.
📅 Data will be presented at The Liver Meeting alongside real-world evidence for Livdelzi.
💰 Gilead stock rose 1.75% to 157.27 euros following the positive trial announcement.
📈 Gilead Sciences reported positive Phase 3 IDEAL results for Livdelzi in primary biliary cholangitis patients with moderately elevated ALP levels.
🔬 At Week 52, 75.4% of participants on Livdelzi achieved the composite endpoint for alkaline phosphatase normalization versus 16.1% on placebo.
📅 The IDEAL study enrolled adults whose ALP levels were above normal but below 1.67 times the upper limit despite ursodeoxycholic acid treatment.
🗣️ Gilead plans to engage global regulatory authorities based on these new clinical milestone results.
🏥 The data will be presented at The Liver Meeting in Denver alongside real-world evidence for Livdelzi and Hepcludex.
💰 Gilead Sciences stock traded 1.75% higher at 157.27 euros following the announcement of the positive clinical trial data.
Bullish Signals
IDEAL study showed 75.4% response rate vs 16.1% placebo.
Livdelzi data expands liver disease pipeline and supports regulatory talks.
Stock rose 1.75% to 157.27 euros on new clinical evidence.
Bullish Signals
Gilead Sciences achieved a 75.4% response rate for alkaline phosphatase normalization in the IDEAL Phase 3 study, significantly outperforming the 16.1% placebo rate.
The positive Livdelzi data expands the company's liver disease pipeline and supports future regulatory discussions with global authorities.
Gilead Sciences stock price increased by 1.75% to 157.27 euros on Thursday, reflecting investor reaction to the new clinical evidence.
Gilead Sciences is preparing to present new clinical and real-world evidence regarding its rare liver disease portfolio at The Liver Meeting 2026 in Denver, scheduled from November 5 to 9. The company has announced a program featuring 21 accepted abstracts focused on primary biliary cholangitis (PBC) and chronic hepatitis delta, marking the next major catalyst for its liver business following recent market activity.
The core of the presentation strategy involves late-breaking Phase 3 results from the IDEAL study evaluating seladelpar, marketed as Livdelzi. This specific presentation on November 8 will examine composite alkaline phosphatase normalization in adults with lower levels of elevation who were taking or unable to tolerate ursodeoxycholic acid, alongside five-year safety and efficacy data.
In addition to PBC updates, Gilead plans to showcase long-term evidence for Hepcludex, its treatment for chronic hepatitis delta virus infection. The program includes a 96-week analysis of combined virologic and biochemical response and a 48-week analysis of clinically significant portal hypertension, aiming to highlight the need for earlier detection and stronger long-term disease management in this rare disease space.
📅 Gilead presents 21 abstracts on PBC and HDV at Liver Meeting 2026.
🔬 IDEAL study shows seladelpar normalizes alkaline phosphatase in adults with lower elevation.
⏳ Five-year safety and efficacy data for seladelpar presented at the conference.
🦠 Hepcludex long-term evidence includes 96-week virologic and biochemical response analysis.
🩸 Gilead stock fell 2.29% to €150.78 with €187.6B market cap on Nov 2.
📅 Gilead Sciences will present 21 abstracts on primary biliary cholangitis and chronic hepatitis delta at The Liver Meeting 2026 in Denver from November 5 to 9.
🔬 A late-breaking Phase 3 presentation from the IDEAL study will evaluate seladelpar (Livdelzi) focusing on alkaline phosphatase normalization in adults with lower levels of elevation.
⏳ The company will present longer-term safety and efficacy evidence for seladelpar through five years of treatment during the conference.
🩺 Gilead plans to address fatigue as a key symptom affecting quality of life for patients with primary biliary cholangitis in its scientific program.
📊 Additional analyses will examine factors affecting eligibility for second-line treatment, adherence, and healthcare use for Livdelzi.
🦠 The company will present long-term and real-world evidence for Hepcludex, including a 96-week analysis of combined virologic and biochemical response.
🩸 A separate presentation will cover a 48-week analysis of clinically significant portal hypertension in people receiving Hepcludex treatment.
📉 Gilead Sciences stock traded at 150.78 euros on November 2, 2026, representing a 2.29 percent decline from the previous Friday's close.
💰 The company's market capitalization was reported at approximately 187.6 billion euros as of November 2, 2026.
Bullish Signals
Gilead presents Phase 3 IDEAL study results for seladelpar in PBC.
Bullish Signals
Gilead Sciences will present late-breaking Phase 3 results from the IDEAL study evaluating seladelpar (Livdelzi) in adults with primary biliary cholangitis.
The company is set to present longer-term safety and efficacy evidence for seladelpar through five years of treatment at the upcoming conference.
Gilead will showcase a 96-week analysis of combined virologic and biochemical response for its hepatitis delta treatment, Hepcludex.
Gilead Sciences is preparing to present new clinical and real-world evidence at The Liver Meeting 2026 in Denver, scheduled from November 5 through November 9. The company announced this scientific program on October 22, focusing on its research into primary biliary cholangitis (PBC) and chronic hepatitis delta virus infection.
The core of the presentation will feature late-breaking Phase 3 data for Livdelzi (seladelpar), specifically regarding composite alkaline phosphatase normalization. Additionally, Gilead plans to showcase long-term efficacy and safety profiles for Hepcludex (bulevirtide) in treating chronic hepatitis delta, including analyses on portal hypertension and disease progression.
For investors, this event serves as a critical readout for clinical development progress rather than an earnings report. The market relevance will hinge on how the presented data influences expectations for Livdelzi and Hepcludex adoption in their respective therapeutic markets, potentially impacting future revenue guidance and stock performance.
Gilead Sciences stock was trading at 152.76 euros on November 1, reflecting a slight decline of 1.01% against the previous Friday's close. While US equities like the S&P 500 provide the broader market backdrop, the specific focus remains on the company's pipeline advancements in liver disease treatments presented at the upcoming conference.
📅 Gilead presents Phase 3 Livdelzi data at Liver Meeting 2026 Nov 5-9.
💊 Highlights include composite alkaline phosphatase normalization in primary biliary cholangitis.
📊 Secured 21 abstracts covering safety, efficacy, and renal function metrics.
📉 Stock traded at €152.76 on Nov 1, down 1.01% from Friday close.
📅 Gilead Sciences will present its scientific program at The Liver Meeting 2026 in Denver from November 5 to November 9.
💊 The presentation highlights late-breaking Phase 3 research for Livdelzi (seladelpar) regarding composite alkaline phosphatase normalization in primary biliary cholangitis.
🔬 Gilead plans to share long-term evidence and real-world data for Hepcludex (bulevirtide) treating chronic hepatitis delta virus infection.
📊 The company has secured 21 accepted abstracts covering safety, efficacy, fatigue, renal function, and treatment adherence metrics.
🗣️ Abstract 5007 on Livdelzi is scheduled as an oral presentation on Sunday, November 8, from 5:00 to 5:15 p.m. Denver time.
📈 The event offers investors a scheduled readout on clinical development and patient outcomes rather than immediate earnings data.
💰 Gilead Sciences stock traded at 152.76 euros on November 1, down 1.01% from the Friday close of 154.32 euros.
🏥 Research topics include integrated efficacy findings and non-invasive fibrosis testing for Hepcludex patients.
📉 The business relevance depends on how presented evidence affects market expectations for Livdelzi and Hepcludex adoption.
Bullish Signals
Livdelzi Phase 3 data shows alkaline phosphatase normalization at The Liver Meeting.
Bullish Signals
Gilead Sciences will present late-breaking Phase 3 research for Livdelzi (seladelpar) at The Liver Meeting, providing new data on composite alkaline phosphatase normalization.
The company plans to showcase long-term and real-world evidence for Hepcludex (bulevirtide), demonstrating sustained efficacy in chronic hepatitis delta treatment.
Gilead has secured 21 accepted abstracts covering comprehensive metrics including five-year safety, fatigue management, renal function, and treatment adherence.
The presentation includes specific analyses on portal hypertension after 48 weeks of Hepcludex treatment and disease progression in chronic hepatitis delta.
Gilead Sciences (GILD) has seen its HIV franchise, led by Biktarvy, face a slowdown in growth momentum following strong returns over the past year. During an August 4, 2026 earnings call, management noted that growth in the HIV treatment market slowed in the second quarter, with Biktarvy sales rising only 7% year-over-year to $3.8 billion. This growth deceleration is attributed partly to a higher average price and inventory build rather than solely new patient demand, signaling a maturing market for the blockbuster drug.
The financial implications of this slowdown are significant for Gilead's valuation and revenue trajectory. Biktarvy accounted for 48.7% of Gilead's fiscal 2025 revenue, contributing approximately $0.9 billion in sales that year. Analysts note that if Biktarvy had remained flat in 2025, it would have erased the company's overall sales growth, potentially causing total revenue to shrink given the high valuation multiple of 6.4 times sales compared to the S&P 500.
Despite the HIV treatment slowdown, Gilead is finding growth in its HIV prevention business and maintains a strong balance sheet. Prevention sales doubled year-over-year in the second quarter, crossing $1 billion for the first time, driven largely by Descovy which grew 30.5% in fiscal 2025. The company generated $12.9 billion in free cash flow over the twelve months to June 2026 and expects full-year HIV sales growth of 9% to 10%, up from previous guidance.
Investors are closely watching Gilead's upcoming third-quarter report expected on October 29 for confirmation of Biktarvy's growth rate and whether HIV sales meet the revised expectations. While the company has sufficient cash reserves to weather a slowdown in its primary revenue driver, the shift away from rapid expansion in HIV treatment poses a strategic challenge that could impact long-term stock performance if prevention growth does not fully offset the decline.
📉 Biktarvy Q2 2026 sales grew 7% to $3.8 billion.
💰 HIV prevention sales doubled, crossing $1 billion in Q2.
🔬 FDA approved new once-daily pill for low viral levels on Aug 27, 2026.
💵 Gilead generated $12.9 billion free cash flow over twelve months ending June 2026.
📈 Management raised full-year HIV sales growth guidance to 9-10%.
📉 Gilead's blockbuster HIV drug Biktarvy saw sales growth slow to 7% in the second quarter of 2026, reaching $3.8 billion.
💰 Biktarvy represented 48.7% of Gilead's fiscal 2025 revenue, contributing $0.9 billion to total sales.
📈 HIV prevention sales doubled year-over-year in the second quarter, crossing $1 billion for the first time.
🔬 The FDA approved a new once-daily combination pill for adults with very low viral levels on August 27, 2026.
💵 Gilead generated $12.9 billion in free cash flow over the twelve months ending June 2026.
📊 Management raised full-year HIV sales growth guidance to 9% to 10%, up from 8% previously.
⚠️ A flat performance from Biktarvy would have wiped out Gilead's overall sales growth in fiscal 2025.
🏥 Descovy, the primary driver of prevention sales, grew 30.5% in fiscal 2025.
📅 Investors are awaiting the third-quarter earnings report expected on October 29 for updated guidance.
Bullish Signals
HIV sales doubled Q2 to cross $1 billion.
Raised full-year HIV growth guidance to 9-10%.
Generated $12.9B free cash flow through June 2026.
New HIV drugs enable market share expansion.
Descovy grew 30.5% in fiscal 2025.
Risk Factors
Biktarvy sales grew only 7% YoY in Q2.
Biktarvy growth halved from 13.3% to 6.8%.
Flat Biktarvy would shrink total revenue in FY25.
HIV market expected to grow slowly at 2-3%.
Bullish Signals
Gilead's HIV prevention business is growing rapidly, with sales doubling year-over-year in the second quarter to cross $1 billion for the first time.
The company raised its full-year HIV sales growth guidance to 9% to 10%, reflecting confidence in non-Biktarvy revenue streams.
Gilead generated robust free cash flow of $12.9 billion over the twelve months to June 2026, providing financial flexibility.
The company's newer HIV drugs offer opportunities to expand market share among patients switching from existing regimens.
Descovy, which drives most prevention sales, achieved strong growth of 30.5% in fiscal 2025.
Risk Factors
Growth in the HIV treatment market slowed in the second quarter, with Biktarvy sales increasing only 7% year-over-year.
Biktarvy's growth rate roughly halved over a single year, dropping from 13.3% in fiscal 2024 to 6.8% in fiscal 2025.
A flat performance from Biktarvy would have caused Gilead's total revenue to shrink in fiscal 2025 given its high reliance on the drug.
The market for HIV treatment is expected to return to a slow typical growth rate of 2% to 3% annually.
Gilead Sciences is preparing to report its third-quarter results on October 29, 2026, following a strong second quarter where total product sales reached $7.60 billion, an 8% year-over-year increase. The company's stock was trading at EUR 139.49 on October 19, 2026, sitting slightly below its 52-week high but well above its low.
Key growth drivers highlighted include HIV sales, which rose 12% to $5.70 billion in the second quarter, and Trodelvy oncology sales, which surged 26% to $457 million. Additionally, the PrEP business exceeded $1 billion in quarterly sales, with management citing a $4 billion annual run rate for this franchise.
Gilead has raised its full-year HIV sales growth guidance to a range of 9-10%, up from 8% previously, while maintaining total product sales guidance between $30.10 billion and $30.40 billion. Analyst Truist Financial recently raised its price target to $158, reflecting confidence in the company's commercial momentum across HIV, oncology, liver disease, and cell therapy segments.
📈 Gilead Q2 sales rose 8% to $7.6B driven by HIV and oncology growth.
💊 HIV segment grew 12% to $5.7B, raising full-year guidance to 9-10%.
🔬 Oncology drug Trodelvy sales jumped 26% to $457 million in Q2.
💰 PrEP business surpassed $1B quarterly sales with a $4B annual run rate.
📈 Truist raised price target to $158; stock trades at EUR 139.49.
📈 Gilead Sciences reported second-quarter total product sales of $7.60 billion, representing an 8% year-over-year increase.
💊 HIV sales grew by 12% to reach $5.70 billion in the second quarter, reinforcing the core franchise's strength.
🔬 Oncology segment saw significant momentum with Trodelvy sales increasing 26% to $457 million.
💰 The PrEP business exceeded $1 billion in quarterly sales, supported by a $4 billion annual run rate.
📊 Management raised full-year HIV sales growth guidance to 9-10%, up from the previous 8% estimate.
🎯 Total product sales guidance for the full year stands between $30.10 billion and $30.40 billion.
📅 Third-quarter earnings are scheduled for release on October 29, 2026, after market close.
🗣️ Management will host a webcast at 4:30 p.m. Eastern Time to discuss the upcoming results.
🏦 Analyst Truist Financial raised its price target to $158 on October 7, 2026.
📉 The stock trades at EUR 139.49, which is 2.32% below its 52-week high of EUR 142.80.
Bullish Signals
Total product sales rose 8% YoY to $7.60B.
HIV sales grew 12% to $5.70B.
Oncology drug Trodelvy sales jumped 26%.
PrEP business hit $1B quarterly with $4B run rate.
Management raised HIV growth guidance to 9-10%.
Bullish Signals
Gilead Sciences achieved an 8% year-over-year increase in total product sales, reaching $7.60 billion in the second quarter.
HIV sales grew robustly by 12% to $5.70 billion, demonstrating continued strength in the company's primary revenue driver.
Oncology franchise Trodelvy delivered a strong 26% sales increase to $457 million, highlighting successful expansion in cancer therapy.
The PrEP business surpassed $1 billion in quarterly sales with a confirmed $4 billion annual run rate, indicating durable growth potential.
Management proactively raised full-year HIV sales growth guidance to 9-10%, signaling confidence in commercial execution.
Analyst Truist Financial increased its price target to $158, reflecting positive sentiment regarding the company's financial outlook.
Gilead Sciences (GILD) has achieved a major milestone in its HIV prevention business, with PrEP sales crossing $1 billion for the first time in a single quarter during fiscal Q2 2026. This segment, which includes medicines taken by virus-negative individuals to prevent infection, doubled from a year earlier and now accounts for approximately 80% of all Descovy sales. The growth is driven primarily by two products: Descovy, an oral daily pill, and Yeztugo, a twice-yearly injection.
Management attributes this strong performance to robust adoption in the U.S. market, which grew roughly 14% year-over-year, and high retention rates for the long-acting Yeztugo injection, with over 70% of users returning for a second dose within six months. While prevention revenue remains significantly smaller than Gilead's core HIV treatment business led by Biktarvy, it offers a distinct growth trajectory, with Descovy sales growing 30.5% in fiscal 2025 compared to 6.8% for Biktarvy.
Looking ahead, Gilead has raised its full-year fiscal 2026 HIV category sales guidance to 9-10%, up from the previous 8% projection, signaling confidence in continued expansion. The company is also expanding its global reach through a new agreement with the Pan American Health Organization to accelerate access to lenacapavir for prevention across Latin America and the Caribbean. Investors have responded positively, driving Gilead shares to their highest level of the past year.
Despite the bullish sentiment, some questions remain regarding the alignment between reported sales and third-party prescription data tracked by firms like IQVIA, though executives declined to comment on external metrics. The market is closely watching upcoming fiscal Q3 2026 results and awaits a regulatory decision expected in early 2027 for a new long-acting oral prevention option, which could further diversify Gilead's pipeline beyond its current offerings.
📈 HIV prevention sales doubled to $1B in Q2 2026.
💊 Descovy drove 80% of prevention revenue at $801M.
🚀 U.S. PrEP market grew 14% YoY with strong retention.
📊 Raised 2026 HIV sales guidance to 9-10%.
🌎 Expanded lenacapavir access in Latin America and Caribbean.
📈 Gilead's HIV prevention sales crossed $1 billion in fiscal Q2 2026, doubling from the prior year and representing a significant new growth engine.
💊 Descovy generated approximately $801 million in prevention revenue during the quarter, accounting for roughly 80% of its total sales.
📉 Yeztugo, Gilead's twice-yearly injection, shows strong retention with over 70% of users returning for a second dose within six months.
🚀 The broader U.S. PrEP market expanded by 14% year-over-year on a growing base of users.
📊 Gilead raised its fiscal 2026 HIV category sales guidance to 9-10%, up from the previously projected 8%.
🌎 The company signed an agreement with the Pan American Health Organization to expand access to lenacapavir for prevention in Latin America and the Caribbean.
📈 Gilead shares closed at a yearly high on October 15, 2026, returning 36.1% over the year versus 17.9% for the S&P 500.
⚖️ The stock trades at 6.4 times sales compared to 3.1 for the S&P 500, reflecting high market expectations for continued growth.
🔍 Investors are monitoring a potential discrepancy between Gilead's reported sales and third-party prescription data tracked by IQVIA.
📅 A regulatory decision on a new long-acting oral prevention option is expected by February 2, 2027.
Bullish Signals
HIV prevention sales exceeded $1B in fiscal Q2 2026.
Risk Factors
Sales vs. IQVIA data gap widens, raising alignment concerns.
Bullish Signals
Gilead's HIV prevention business achieved a historic milestone with quarterly sales exceeding $1 billion in fiscal Q2 2026.
Prevention revenue doubled year-over-year, driven by strong performance from both Descovy and the new Yeztugo injection.
The U.S. PrEP market grew approximately 14% year-over-year, indicating expanding demand for HIV prevention therapies.
High retention rates for Yeztugo demonstrate product efficacy, with over 70% of users returning for a second dose within six months.
Gilead raised its full-year fiscal 2026 HIV category sales guidance to 9-10%, reflecting management's confidence in the business.
Descovy continues to be a major revenue driver, growing 30.5% in fiscal 2025 compared to 6.8% for the core treatment product Biktarvy.
The company secured a strategic partnership with the Pan American Health Organization to expand access to its long-acting prevention drug in Latin America and the Caribbean.
Gilead stock price surged, closing at a yearly high on October 15, 2026, with shares up 36.1% for the year.
Risk Factors
There is a noted widening gap between Gilead's reported sales and third-party prescription figures tracked by IQVIA, raising questions about data alignment.
Bank of America raised its price target for Gilead Sciences stock from USD 162.00 to USD 164.00 on October 12, 2026, while maintaining a Buy rating. The analyst view remains tied to the company's commercial execution rather than awaiting new corporate announcements. At the time of the report, Gilead Sciences stock was trading at approximately USD 156.34, placing the new target about 4.90 percent above the current market price.
The revision is supported by BofA's modeling of third-quarter Biktarvy sales at USD 3.922 billion, which exceeds the consensus estimate of USD 3.908 billion by USD 14 million. This specific operating metric provides investors with a measurable reference point for the upcoming earnings release scheduled for October 29, 2026, after market close.
As of mid-October 2026, Gilead Sciences holds a market capitalization of USD 193.9 billion and trades within a 52-week range of USD 114.02 to USD 160.51. The company's P/E ratio is listed as minus 58.60, reflecting its biotech sector status where earnings multiples may differ from traditional metrics due to significant R&D investments or specific accounting treatments.
📈 Bank of America raised Gilead price target to USD 164.00 on October 12, 2026.
💊 BofA models Q3 Biktarvy sales at USD 3.922 billion, beating consensus by USD 14 million.
📅 Gilead scheduled to release third-quarter results after market close on October 29, 2026.
💰 Market cap is USD 193.9 billion with stock trading at USD 156.34 as of mid-October 2026.
📈 Bank of America raised its price target for Gilead Sciences stock from USD 162.00 to USD 164.00 on October 12, 2026.
🔍 The analyst maintains a Buy rating and ties the outlook to Gilead's commercial execution rather than new corporate announcements.
💊 BofA models third-quarter Biktarvy sales at USD 3.922 billion, beating the consensus estimate of USD 3.908 billion by USD 14 million.
📅 Gilead Sciences is scheduled to release its third-quarter results after market close on October 29, 2026.
💰 As of mid-October 2026, the company has a market capitalization of USD 193.9 billion and trades at USD 156.34.
📉 The stock's P/E ratio is reported as minus 58.60, while the dividend yield stands at 0.02 percent.
Bullish Signals
Bank of America raised price target to $164 with Buy rating.
Q3 Biktarvy sales hit $3.922B, beating estimates by $14M.
Bullish Signals
Bank of America raised its price target for Gilead Sciences from USD 162.00 to USD 164.00 while maintaining a Buy rating.
Analysts model third-quarter Biktarvy sales at USD 3.922 billion, which exceeds the consensus estimate of USD 3.908 billion by USD 14 million.
Gilead Sciences (NASDAQ: GILD) has significantly outperformed the broader market, surging over 24% year-to-date compared to the S&P 500's 14% return. Despite this rally, the stock trades at a normalized forward P/E of approximately 15.5x, which analysts view as reasonable given the company's underlying business growth and durable HIV franchise.
The core driver for Gilead's valuation is its robust performance in the HIV segment. In the second quarter of 2026, total revenue increased 10% year-over-year to $7.8 billion, with HIV product sales growing 12% to $5.7 billion led by Biktarvy. Additionally, the company secured FDA approvals for Yeztugo, a long-acting HIV prevention option, and Hepcludex, the first approved treatment for chronic hepatitis delta virus infection in the U.S.
Beyond its core franchise, Gilead is investing heavily in new growth engines through acquisitions like Arcellx, Tubulis, and Ouro Medicines, which incurred $11.2 billion in in-process R&D charges in Q2 2026 alone. While these charges caused a reported loss of $8.45 per share, the company's strategy relies on these technologies to expand beyond HIV. However, oncology faces headwinds with cell therapy sales falling 14% due to competition, and the stock's valuation cushion has narrowed as investors price in both the durability of its existing business and the potential payoff from expensive pipeline investments.
💰 Normalized forward P/E is 15.5x excluding acquisition charges.
🔬 Q2 revenue rose 10% to $7.8B driven by HIV growth.
✅ FDA approved Yeztugo and Hepcludex for new indications.
⚠️ Oncology sales fell 14% amid competition and high R&D costs.
📈 Gilead Sciences stock surged over 24% year-to-date, significantly outperforming the S&P 500's 14% return.
💰 The company trades at a normalized forward P/E of approximately 15.5x based on earnings expectations rather than reported EPS distorted by acquisition charges.
🔬 Q2 2026 total revenue increased 10% year-over-year to $7.8 billion, driven by strong HIV franchise performance.
💊 HIV product sales grew 12% to $5.7 billion in the second quarter, with Biktarvy sales rising 7% to $3.8 billion.
✅ Gilead received FDA approval for Yeztugo, a long-acting HIV prevention option, and Hepcludex for chronic hepatitis delta virus infection.
🧬 The company secured FDA acceptance for an application regarding a potential once-weekly oral formulation for HIV pre-exposure prophylaxis.
📉 Oncology segment faces challenges with cell therapy sales falling 14% in Q2, specifically Yescarta down 12% and Tecartus down 24% due to competition.
💸 Acquisitions of Arcellx, Tubulis, and Ouro Medicines resulted in $11.2 billion of acquired in-process R&D expenses in the second quarter alone.
📉 Reported diluted loss per share reached $(8.45) in Q2 2026 due to acquisition-related IPR&D charges impacting earnings.
⚖️ Analysts note that while the valuation is defensible, Gilead must generate sufficient returns from its new technologies to justify higher expectations post-rally.
Bullish Signals
Stock gained 24% YTD vs S&P 500's 14%.
HIV revenue rose 10% YoY to $7.8B.
HIV sales grew 12% to $5.7B in Q2.
FDA approved Yeztugo for HIV prevention.
Hepcludex approved for hepatitis delta virus.
Risk Factors
Q2 2026 diluted loss hit $(8.45) due to $9.08 IPR&D charges.
Cell therapy sales fell 14%; Yescarta down 12%, Tecartus down 24%.
Valuation cushion narrowed after 28% share price rally over past year.
Investors pay premium for HIV franchise and new technology potential.
Bullish Signals
Gilead Sciences stock has outperformed the S&P 500 with a year-to-date gain of over 24% compared to the index's 14% return.
The company's core HIV franchise remains a strong growth driver, with total revenue increasing 10% year-over-year to $7.8 billion in Q2 2026.
HIV product sales grew 12% to $5.7 billion in the second quarter, demonstrating the durability of the company's largest existing franchise.
Gilead received FDA approval for Yeztugo, a long-acting HIV prevention option, expanding its portfolio in the high-growth HIV market.
The company secured FDA accelerated approval for Hepcludex, becoming the first and only FDA-approved treatment for chronic hepatitis delta virus infection in the United States.
Oncology segment shows growth potential with Trodelvy sales increasing 26% year-over-year to $457 million in Q2 2026.
Risk Factors
Reported diluted loss per share reached $(8.45) in Q2 2026, driven by approximately $9.08 per share in acquisition-related IPR&D charges.
Cell therapy sales fell 14% in the second quarter, with Yescarta down 12% and Tecartus down 24%, primarily due to increased competition.
The stock's valuation cushion has narrowed as the share price rallied 28% over the past year, reducing the margin of safety compared to pre-rally levels.
Investors are now paying a premium that reflects both the durability of the HIV franchise and the potential payoff from billions invested in new technologies.
Gilead Sciences (GILD) has experienced a significant multi-year stock appreciation of 167.1% over the past five years, prompting investors to reassess whether current share prices align with the company's underlying sales power and revenue base. Recent reports indicate that while HIV treatment product sales have strengthened, reported earnings face pressure due to acquisition charges and margin dynamics, creating a divergence between top-line growth and profitability.
Analysts utilizing Simply Wall St's valuation framework suggest Gilead trades at a Price-to-Sales (P/S) multiple of 6.2x, which is notably lower than the biotech sector average of 12.2x and its peer group average of 7.1x. The Fair Ratio model indicates that despite strong Q2 revenue and upbeat headlines regarding product sales, the market is currently pricing Gilead's sales below what its growth profile, margins, and scale would typically warrant.
Community sentiment regarding Gilead Sciences is divided between a bullish view of roughly fair valuation and a bearish perspective suggesting the stock is 18% overvalued. The bull case highlights the rapid scaling of the HIV prevention franchise, specifically noting that Yeztugo is expected to contribute approximately US$1 billion in its first full launch year into a roughly US$4 billion annual PrEP portfolio. Conversely, the bear case cites execution risks related to M&A integration, oncology competition, pricing pressure, and near-term EPS dilution as primary concerns.
📈 GILD stock gained 167.1% over five years despite valuation questions.
💰 Higher HIV sales offset by acquisition charges lowering earnings.
📊 GILD trades at 6.2x P/S, below sector and peer averages.
🚀 Yeztugo expected to add $1B to the $4B PrEP portfolio.
⚠️ Risks include M&A integration, oncology competition, and pricing pressure.
📈 Gilead Sciences stock has returned 167.1% over the past five years, raising questions about current valuation alignment with sales power.
💰 Recent data shows higher HIV treatment product sales alongside weaker reported earnings due to acquisition charges affecting profit conversion.
📊 The company trades at a P/S multiple of 6.2x, which is below both the biotech sector average of 12.2x and peer group average of 7.1x.
🚀 Yeztugo is expected to contribute about US$1 billion in its first full launch year into a roughly US$4 billion annual PrEP portfolio.
⚠️ Bear case analysts identify execution risks including M&A integration challenges, oncology competition, and pricing pressure as key concerns.
📉 Community views split between those seeing runway in HIV/oncology engines and those focusing on near-term EPS dilution risks.
Gilead Sciences (GILD) demonstrates strong cash generation capabilities, producing free cash flow equal to 7.1% of its market value over the last twelve months, significantly higher than the S&P 500 median of 4.5%. The company's operating margin stands at 38.5%, driven largely by its blockbuster HIV drug Biktarvy, which accounted for $14.3 billion of the $29.4 billion total revenue in fiscal 2025. Despite carrying net debt equal to 12.6% of market value, Gilead comfortably covers interest obligations with an operating profit coverage ratio of 11.7x.
However, investors are pricing in risks related to the company's heavy reliance on HIV treatments and declining performance in non-HIV segments. Specifically, sales for Veklury were lowered to approximately $300 million for the full year, and cell therapy revenue fell 14% due to market competition. To mitigate this concentration risk, Gilead spent $11.2 billion on research programs and acquisitions during the quarter, though these expenses contributed to a net loss of $3.2 billion over the last twelve months.
Looking ahead, management has raised its forecast for HIV sales growth to 9-10% for fiscal 2026, signaling confidence in its core business expansion despite the contraction elsewhere. The stock currently lacks a meaningful P/E ratio due to the net loss, but the high cash yield suggests the market may be undervaluing the company's durable cash-generating assets if HIV growth targets are met and non-HIV declines stabilize.
📈 Gilead generated free cash flow equal to 7.1% of market value, outpacing S&P 500 median yield.
💊 HIV drug Biktarvy drove $14.3 billion revenue with a robust 38.5% operating margin.
📉 Veklury sales lowered to $300 million; cell therapy sales declined 14% due to competition.
💰 Gilead spent $11.2 billion on research and acquisitions to diversify beyond HIV treatments.
🚀 Management raised full-year 2026 HIV sales growth forecast to 9-10%.
📈 Gilead generated free cash flow equal to 7.1% of its market value over the last twelve months, significantly outpacing the S&P 500 median yield of 4.5%.
💊 The HIV drug Biktarvy drove $14.3 billion of Gilead's $29.4 billion fiscal 2025 revenue, contributing to a robust 38.5% operating margin.
📉 Sales for the non-HIV drug Veklury were lowered to approximately $300 million for the full year, down from an earlier forecast of $600 million.
🔬 Cell therapy sales declined 14% year-over-year in the most recent quarter due to increased market competition.
💰 Gilead spent $11.2 billion on outside research programs and acquisitions during the quarter to diversify its portfolio beyond HIV treatments.
📉 The company reported a net loss of $3.2 billion over the last twelve months, resulting in no meaningful P/E ratio for the stock.
🚀 Management raised its full-year 2026 HIV sales growth forecast to a range between 9% and 10%, up from the previous 8% guidance.
⚖️ Gilead's operating profit covers its interest bill 11.7 times over, indicating strong ability to service its net debt of 12.6% of market value.
Bullish Signals
Free cash flow hit $12.9B, up from $9.4B last year.
Operating margin reached 38.5%, driven by HIV drug Biktarvy.
HIV sales growth forecast for 2026 raised to 9-10% range.
Free cash flow yield of 7.1% exceeds S&P 500 median.
Interest coverage ratio stands at 11.7x, ensuring debt safety.
Risk Factors
Heavy reliance on HIV treatments creates significant market risk.
Non-HIV drug Veklury sales lowered to $300M from $600M forecast.
Cell therapy revenue fell 14% due to competition pressures.
Net loss of $3.2B over last twelve months.
Cash generation growth challenged by declining Veklury and cell therapy sales.
Bullish Signals
Gilead generated free cash flow equal to 7.1% of its market value over the last twelve months, significantly exceeding the S&P 500 median yield of 4.5%.
The company achieved a high operating margin of 38.5%, driven by the blockbuster HIV drug Biktarvy which generated $14.3 billion in revenue.
Free cash flow expanded to $12.9 billion over the last twelve months, up from $9.4 billion a year earlier, demonstrating growing capital generation.
Management raised its forecast for 2026 HIV sales growth to a range between 9% and 10%, indicating confidence in the expansion of its largest business segment.
Gilead comfortably covers its interest obligations with an operating profit coverage ratio of 11.7x, ensuring debt service is not a constraint on cash returns.
Risk Factors
The market prices in significant risks due to the company's heavy reliance on HIV treatments and declining sales in non-HIV segments.
Sales for the non-HIV drug Veklury were lowered to approximately $300 million for the full year, down from a previous forecast of $600 million.
Cell therapy revenue fell 14% from a year earlier during the quarter due to market competition pressures.
Gilead reported a net loss of $3.2 billion over the last twelve months due to acquisition charges, resulting in no meaningful P/E ratio for valuation.
The company faces the challenge of proving that cash generation will continue to grow despite the contraction in Veklury and cell therapy sales.
Gilead Sciences (GILD) received a rating downgrade from Zacks Research, which cut the stock from a strong buy to a hold on October 1, 2026. This analyst action contrasts with a broader positive consensus among other market participants, where 23 analysts maintain Buy ratings versus six Hold ratings, resulting in an average price target of USD 158.78.
Financially, Gilead reported robust performance for the second quarter of 2026, posting revenue of USD 7.80 billion, a 10% year-over-year increase that exceeded consensus estimates of USD 7.37 billion. Excluding Veklury, product sales grew 10% to USD 7.60 billion, driven by strong growth in its core HIV franchise.
Specifically, HIV sales surged 12% to USD 5.70 billion while Biktarvy sales increased 7% to USD 3.80 billion. Management subsequently raised full-year 2026 HIV sales growth guidance to a range of 9-10%, up from the previous 8% expectation, signaling confidence in the durability of its treatment base.
The market reaction remained muted with shares trading slightly higher at EUR 128.93 on October 6, 2026, despite the Zacks downgrade. The company's market capitalization stands at USD 179.3 billion as investors weigh the strong current performance against expectations for new prevention products to extend growth beyond its established HIV portfolio.
📉 Zacks downgraded GILD to Hold on Oct 1, 2026.
💰 Q2 2026 revenue hit $7.8B, beating estimates.
🚀 Management raised full-year HIV growth guidance to 9-10%.
🏦 MarketBeat consensus is Moderate Buy with $158.78 target.
📈 HSBC raised price target to $175 while keeping Buy.
📉 Zacks Research downgraded Gilead Sciences from a strong buy to a hold rating on October 1, 2026.
📈 HIV sales grew 12% to USD 5.70 billion in the second quarter of 2026.
💊 Biktarvy sales increased 7% to USD 3.80 billion during the same reporting period.
🚀 Management raised full-year 2026 HIV sales growth guidance to 9-10% from 8%.
📊 The stock exceeded consensus revenue estimates of USD 7.37 billion in Q2 2026.
🏦 MarketBeat reports a Moderate Buy consensus with an average price target of USD 158.78.
📉 HSBC raised its price target to USD 175.00 while maintaining a Buy rating on September 10, 2026.
💹 Gilead Sciences stock traded at EUR 128.93 on October 6, 2026, up 0.11% from the prior close.
🏢 The company maintains a market capitalization of USD 179.3 billion as of October 5, 2026.
Bullish Signals
Q2 2026 revenue hit USD 7.80B, beating estimates.
HIV sales grew 12% YoY to USD 5.70B.
Biktarvy sales rose 7% to USD 3.80B.
Management raised full-year HIV growth guidance to 9-10%.
Risk Factors
Zacks downgraded to Hold amid growth concerns.
Scrutiny on new products extending HIV base.
Bullish Signals
Gilead Sciences reported second-quarter 2026 revenue of USD 7.80 billion, which exceeded the consensus estimate of USD 7.37 billion.
HIV sales grew 12% year-over-year to reach USD 5.70 billion in the second quarter of 2026.
Biktarvy sales increased 7% to USD 3.80 billion, demonstrating strong performance for the company's key asset.
Management raised full-year 2026 HIV sales growth guidance to a range of 9-10%, up from the prior 8% expectation.
The broader analyst consensus remains positive with 23 Buy ratings versus only six Hold ratings.
Risk Factors
Zacks Research downgraded Gilead Sciences from a strong buy to a hold rating, citing expectations after a strong run.
The rating downgrade highlights investor scrutiny regarding whether new prevention products can extend growth beyond the established HIV treatment base.
Gilead Sciences (NASDAQ:GILD) reported a strong second quarter driven by its HIV franchise, which generated $5.69 billion in sales, representing roughly three-quarters of total product revenue. Key HIV products showed robust growth, with Biktarvy sales rising 7% to $3.8 billion and Descovy jumping 48% to $967 million. The company also saw significant gains in its liver-disease segment, where Livdelzi revenue more than doubled to $167 million.
Beyond HIV, Gilead demonstrated mixed performance outside its core franchise. While Trodelvy sales increased 26% to $457 million, cell therapy revenues declined 14% amid competitive pressures, and Yescarta fell 12%. Despite these variances, the company raised its 2026 product-sales guidance to a range of $30.1 billion-$30.4 billion and increased its quarterly dividend by 3.8% to $0.82 per share starting in 2026.
The article highlights Gilead's strategic trade-offs, noting that while it offers stronger current growth momentum, the business carries significant concentration risk due to its heavy reliance on HIV therapies. Additionally, the company recorded substantial one-time charges related to acquisitions of Arcellx, Tubulis, and Ouro Medicines, resulting in GAAP quarterly losses per share of $8.45. These factors position Gilead as a high-growth but concentrated investment compared to more diversified peers.
📈 HIV franchise sales excluding Veklury rose 10% to $7.6 billion in Q2.
💊 Biktarvy grew 7% while Descovy surged 48% to $967 million.
🔬 Liver-disease revenue increased 10%, led by Livdelzi doubling to $167 million.
📉 Cell Therapy sales fell 14% to $417 million amid competition.
💰 Raised 2026 guidance to $30.1-$30.4B and dividend by 3.8%.
📈 Gilead's HIV franchise drove strong Q2 performance with product sales excluding Veklury increasing 10% to $7.6 billion.
💊 Biktarvy sales grew 7% to $3.8 billion while Descovy surged 48% to $967 million in the second quarter.
🔬 Liver-disease segment revenue increased 10% to $877 million, led by Livdelzi doubling from $78 million to $167 million.
📉 Cell Therapy sales declined 14% to $417 million and Yescarta fell 12% amid competitive headwinds.
💰 Gilead raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion and increased the quarterly dividend by 3.8%.
⚠️ The company faces concentration risk as HIV sales account for roughly three-quarters of total product revenue.
💸 Acquisitions of Arcellx, Tubulis, and Ouro Medicines resulted in $11.2 billion in acquired in-process R&D expenses.
📊 GAAP quarterly losses per share reached $8.45 due to acquisition-related charges and non-GAAP losses of $6.75.
Bullish Signals
HIV sales excluding Veklury rose 10% to $7.6B in Q2.
Descovy revenue jumped 48% to $967M and Biktarvy up 7%.
Liver-disease segment sales grew 10% to $877M driven by Livdelzi.
Raised 2026 guidance to $30.1B-$30.4B and dividend by 3.8%.
Risk Factors
Revenue concentrated in HIV creates significant risk.
Cell therapy sales dropped 14% to $417M.
Bullish Signals
Gilead's HIV franchise continues to gain momentum with product sales excluding Veklury increasing 10% to $7.6 billion in Q2.
Key HIV products showed exceptional growth, with Descovy revenue jumping 48% to $967 million and Biktarvy rising 7% to $3.8 billion.
The liver-disease segment delivered strong results with sales increasing 10% to $877 million, driven by a doubling in Livdelzi revenue.
Management raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion and increased the quarterly dividend by 3.8% to $0.82 per share.
Risk Factors
Approximately three-quarters of Gilead's product revenue comes from its HIV franchise, creating significant concentration risk.
Cell Therapy sales declined 14% to $417 million and Yescarta fell 12%, indicating uneven performance outside the HIV core business.
Gilead Sciences reported second-quarter 2026 revenue of USD 7.80 billion, representing a 10 percent increase from the prior-year quarter and surpassing analyst consensus estimates. This growth was driven primarily by HIV product sales, which rose 12 percent to USD 5.69 billion, while cell-therapy sales declined 14 percent to USD 417 million.
Despite the top-line revenue expansion, Gilead's reported adjusted earnings per share fell to a loss of USD 6.75, which was narrower than the consensus expectation of a USD 7.07 loss. The company attributed this volatility largely to acquisition-related in-process research and development expenses incurred during the quarter.
Looking ahead, Gilead maintained its full-year 2026 product-sales guidance between USD 30.10 billion and USD 30.40 billion. Additionally, the company lifted its HIV sales-growth outlook to a range of 9 percent to 10 percent, signaling continued confidence in its core franchise despite recent stock price weakness.
Analyst sentiment remains positive with HSBC raising its price target to USD 175 and maintaining a Buy rating, while MarketBeat reports a Moderate Buy consensus. The company also declared a quarterly dividend of USD 0.82 per share payable on September 29, 2026.
📈 Q2 2026 revenue hit USD 7.8B, up 10% year-over-year.
💊 HIV sales surged 12% to USD 5.69B driving growth.
🎯 Full-year 2026 guidance maintained at USD 30.1B–30.4B.
🚀 HIV sales-growth outlook lifted to 9-10% from 8%.
📈 Gilead Sciences reported Q2 2026 revenue of USD 7.80 billion, up 10 percent year-over-year and above the Zacks consensus estimate of USD 7.37 billion.
💊 HIV product sales surged 12 percent to USD 5.69 billion, serving as the primary driver for overall revenue growth in the quarter.
📉 Cell-therapy sales declined 14 percent to USD 417 million, contributing to a reported adjusted loss of USD 6.75 per share.
🎯 The company maintained its full-year 2026 product-sales guidance range of USD 30.10 billion to USD 30.40 billion despite the acquisition-related charges.
📈 HSBC raised its price target to USD 175 from USD 155 and maintained a Buy rating following the earnings release.
💰 Gilead declared a quarterly dividend of USD 0.82 per share payable on September 29, 2026.
📊 The stock traded at USD 149.69 on September 24, 2026, down 1.11 percent despite the positive revenue beat.
🚀 Gilead lifted its HIV sales-growth outlook to 9-10 percent from the previous 8 percent forecast.
Bullish Signals
Q2 revenue hit $7.8B, beating estimates with +12% HIV sales growth.
Risk Factors
Cell-therapy sales fell 14% to USD 417 million.
Adjusted EPS was a loss of USD 6.75.
Stock fell 1.11% amid earnings volatility.
Bullish Signals
Gilead Sciences achieved Q2 revenue of USD 7.80 billion, beating analyst estimates and demonstrating strong top-line growth driven by a 12% increase in HIV sales.
The company maintained its full-year 2026 product-sales guidance between USD 30.10 billion and USD 30.40 billion, indicating stable long-term expectations.
HSBC raised its price target to USD 175 from USD 155 and reaffirmed a Buy rating, reflecting strong institutional confidence in the stock.
Gilead increased its HIV sales-growth outlook to 9-10 percent, showing management's optimism for its core franchise performance.
The reported adjusted loss was narrower than expected at USD 6.75 versus a consensus loss of USD 7.07, mitigating downside risk.
Risk Factors
Cell-therapy sales fell 14 percent to USD 417 million in the second quarter, highlighting weakness in the company's emerging biotech portfolio.
The reported adjusted earnings per share were a loss of USD 6.75 due to significant acquisition-related in-process research and development expenses.
Despite revenue growth, Gilead Sciences stock fell 1.11 percent to close at USD 149.69, suggesting investors are pricing in the near-term earnings volatility.
Gilead Sciences reported quarterly revenue of USD 7.80 billion for the period ending in September 2026, representing a 10.6 percent year-over-year increase. This sales figure significantly exceeded analyst consensus estimates by USD 400 million, with the company closing at USD 149.56 on the Nasdaq. Despite the strong top-line performance and a share price that remained below its 52-week high of USD 157.29, the stock experienced a slight decline of 0.7 percent from the prior session.
The company posted earnings per share (EPS) of negative USD 6.75, which was better than the consensus estimate of negative USD 7.25, resulting in a positive variance of USD 0.50. Gilead also declared a quarterly dividend of USD 0.82 per share, annualizing to USD 3.28. Erste Group Bank revised its fiscal 2026 EPS forecast upward to negative USD 0.44 from negative USD 0.45, placing its projection slightly above the broader market consensus.
Analyst sentiment remains cautiously optimistic with a Moderate Buy consensus rating and an average price target of USD 158.78, which sits approximately USD 9.22 above the current closing price. The market capitalization stood at USD 186.69 billion as of September 22, 2026. Investors are now awaiting the next earnings report scheduled for October 22, 2026, to assess continued growth momentum.
📈 Revenue hit USD 7.80B, beating estimates by USD 400M.
💰 EPS loss narrowed to negative USD 6.75 vs estimate.
💵 Quarterly dividend declared at USD 0.82 per share.
🎯 Moderate Buy consensus with USD 158.78 price target.
📅 Next earnings report scheduled for October 22, 2026.
📈 Gilead Sciences reported quarterly revenue of USD 7.80 billion, a 10.6 percent year-over-year increase that beat analyst estimates by USD 400 million.
💰 The company posted EPS of negative USD 6.75, surpassing the consensus estimate of negative USD 7.25 by USD 0.50.
💵 Gilead declared a quarterly dividend of USD 0.82 per share, equivalent to USD 3.28 on an annualized basis.
📉 The stock closed at USD 149.56, down 0.7 percent from the prior close and trading below its 52-week high of USD 157.29.
🏦 Erste Group Bank raised its fiscal 2026 EPS estimate to negative USD 0.44, positioning its forecast above the consensus of negative USD 0.48.
🎯 Analysts maintain a Moderate Buy consensus with an average price target of USD 158.78, roughly USD 9.22 higher than the current share price.
📅 The next earnings report for Gilead is scheduled to be released on October 22, 2026.
💼 As of September 22, 2026, Gilead Sciences had a market capitalization of USD 186.69 billion within the Health Care sector.
Bullish Signals
Revenue beat estimates by $400M at $7.80B.
EPS of -$6.75 was $0.50 better than consensus.
Declared quarterly dividend of $0.82 per share.
Analyst raised 2026 EPS forecast to -$0.44.
Risk Factors
Stock fell 0.7% despite revenue growth.
Shares remain 4.9% below 52-week high of $157.29.
Bullish Signals
Gilead Sciences beat quarterly revenue estimates by USD 400 million, reporting USD 7.80 billion in sales compared to the consensus of USD 7.40 billion.
The company delivered EPS of negative USD 6.75, which was USD 0.50 better than the analyst consensus estimate of negative USD 7.25.
Gilead declared a quarterly dividend of USD 0.82 per share, providing an annualized yield equivalent to USD 3.28 per share.
Erste Group Bank raised its fiscal 2026 EPS forecast for Gilead to negative USD 0.44, indicating confidence in the company's financial trajectory.
Risk Factors
Despite strong revenue growth, Gilead Sciences stock closed down 0.7 percent and remained 4.9 percent below its 52-week high of USD 157.29.
Gilead Sciences stock closed at USD 150.56 on the Nasdaq on September 21, 2026, marking a slight decline of 0.19 percent against a backdrop where the broader Nasdaq Composite rose 2.26 percent to 27,122.09. The company's share price finished lower than the reference index despite the general market gain.
Simply Wall St reported on September 22, 2026, that Gilead maintains HIV prevention access agreements involving royalty-free lenacapavir licenses in 120 high-incidence countries and an agreement with the Pan American Health Organization. These strategic partnerships are central to the company's ongoing efforts to expand access to its key therapeutic assets globally.
A dividend is scheduled to be payable on September 29, 2026, providing income to shareholders ahead of the next quarterly earnings release estimated for October 29, 2026. Market valuations cited in separate reports suggest a fair value of USD 128.38, contrasting with the current trading price of USD 150.56.
The article notes that Gilead Sciences is identified by ISIN US3755581036 and operates within the biopharmaceutical sector, with specific focus on its HIV prevention portfolio and upcoming financial reporting schedule.
📉 GILD stock closed at $150.56, down 0.19% vs Nasdaq gain.
💰 Dividend payable to GILD shareholders on September 29, 2026.
📅 Next quarterly earnings estimated for October 29, 2026.
🌍 HIV access agreements cover lenacapavir in 120 countries royalty-free.
💵 Separate valuation cites fair value of $128.38 for GILD.
📉 Gilead Sciences stock finished at USD 150.56 on September 21, 2026, down 0.19 percent while the Nasdaq Composite gained 2.26 percent.
💰 A dividend is scheduled to be payable on September 29, 2026, for shareholders of Gilead Sciences.
📅 The next quarterly earnings release for Gilead Sciences is estimated for October 29, 2026.
🌍 Gilead holds HIV prevention access agreements involving royalty-free lenacapavir licenses in 120 high-incidence countries.
🤝 Gilead has an active agreement with the Pan American Health Organization regarding its HIV prevention portfolio.
💵 A separate valuation narrative cited a fair value of USD 128.38 for Gilead Sciences stock.
Bullish Signals
Royalty-free lenacapavir licenses in 120 countries expand HIV prevention access.
Secured PAHO agreement to support global HIV prevention initiatives.
Risk Factors
Stock slipped 0.19% on Sept 21, 2026, underperforming Nasdaq.
Fair value of $128.38 is below current price.
Bullish Signals
Gilead Sciences maintains HIV prevention access agreements involving royalty-free lenacapavir licenses in 120 high-incidence countries, expanding global reach.
Gilead has secured an agreement with the Pan American Health Organization to support its HIV prevention initiatives.
Risk Factors
Gilead Sciences stock slipped 0.19 percent on September 21, 2026, underperforming the Nasdaq Composite which rose 2.26 percent.
A separate valuation narrative cited a fair value of USD 128.38, which is lower than the current trading price of USD 150.56.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)